Table 3 Reassessment of HER2 FISH results in ISH Group 2, 3 and 4 based on the 2018 ASCO/CAP guidelines.

From: Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results

 

Cases (N)

IHC result (N)

Recounting FISH in cases scored IHC 2 + (N)

HER2 negative

HER2 positive

ISH group 2

29

0

8

  

1+

14

  

2+

7

7

0

3+

0

  

ISH grouop3

4

0

0

  

1+

1

  

2+

2

2

0

3+

1

  

ISH group 4

53

0

8

  

1+

21

  

2+

15

14

1*

3+

9

  
  1. N: number of cases; IHC: immunohistochemistry; FISH: fluorescence in situ hybridization.
  2. *The result was derived from repeat FISH testing using another tissue sample with a HER2/CEP17 ratio of 2.19 and an average of 8.03 HER2 signals per cell.
Back to article page